The first Russian generic for hemochromatosis therapy has been registered


In October 2022, PSK Pharma received a registration certificate for Deferasirox PSK in the form of dispersible tablets in three dosages: 125 mg, 250 mg, and 500 mg. This product became the first fully Russian dispersible drug with deferasirox as the active substance for the treatment of iron poisoning. This is reported on the official website of Rus Biopharm group of companies.

It is stated that the drug is taken on an empty stomach, 30 minutes before meals, 1 time a day, approximately at the same time, by dissolving the tablet in 100-200 ml of water or juice.

“With early detection and proper treatment, a person with excess iron can live a long and healthy life. First of all, the main causes of excess iron in the body include hemochromatosis, a genetic disorder that leads to increased absorption of iron. A similar effect can be produced by multiple blood transfusions, excessive destruction of red blood cells, or consumption of large amounts of iron-containing drugs,” the report says.

In addition to bloodletting, modern medicine offers patients iron chelating therapy, e. g., Deferasirox. When taken orally, Deferasirox effectively reduces the iron content in the body and promotes its excretion. Deferasirox is included in the list of vital and essential drugs approved by the Government of the Russian Federation, Rus Biopharm Group of Companies added.

As it became known earlier, the offset contract for 4.5 billion rubles was signed by the government of the Moscow region and PSK Pharma.